SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial

Results demonstrated that combining SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption

TEL AVIV, Israel, March 17, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced positive results from a pre-clinical trial as part of its ongoing collaboration agreement with Clearmind Medicine Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0). Results showed a significant dose dependent effect for the MEAI treatment in reducing alcohol consumption of the treated animals, with additional significant effect for the CannAmide™ treatment at the lower sub-effective MEAI dose.

Results showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and at higher doses (p